Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Anti-H3.3K27M TCR-expressing T-cells
- Development stage
- Phase 1
- Lead developer
- University of California, San Francisco
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Autologous Anti-H3.3K27M TCR-expressing T-cells are a form of T cell-based immunotherapy designed to target the H3.3K27M mutation found in diffuse midline gliomas (DMGs). This therapy involves collecting a patient's own T cells, genetically modifying them to express a T cell receptor (TCR) that specifically recognizes the H3.3K27M mutation, and then reinfusing these cells back into the patient to target and kill cancer cells expressing this mutation. The therapy is currently being investigated in clinical trials, particularly for pediatric and young adult patients with H3.3K27M-positive diffuse midline gliomas who are HLA-A*0201-positive. The treatment involves a conditioning regimen with fludarabine and cyclophosphamide followed by intravenous infusion of the modified T cells.
- Other names
- KIND T cells
02
Targets
H3.3K27M/HLA-A*02:01 (Histone H3.3-K27M neoantigen)
Beyond the preview
Go deeper on Autologous Anti-H3.3K27M TCR-expressing T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Anti-H3.3K27M TCR-expressing T-cells.